Combination therapyPhase 3 trialInvestigational
Pembrolizumab + Vemurafenib
How it works
Combines a PD-1 inhibitor (pembrolizumab) with a BRAF inhibitor (vemurafenib) to block cancer cell growth and survival.
Cancer types
Melanoma— BRAF V600E mutation-positive
Efficacy
In clinical trials, around 50% of patients achieved an objective response, with a median overall survival of approximately 22.5 months.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.